BioArctic

BioArctic Earnings Yield

The Earnings Yield of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 3.73 %. In the previous year, Earnings Yield was -0.65 % — a change of -677.33% (higher).

Earnings Yield

3.73 %

YoY

-677.33%

Last updated:

Earnings Yield of BioArctic is 2025 3.73 % . Earnings Yield of BioArctic was 2024 -0.65 % . It decreases by -677.33% higher compared to the previous year.

The BioArctic Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
1.39 SEK
Jan 1, 2019
0.32 SEK
Jan 1, 2020
-0.25 SEK
Jan 1, 2021
-0.44 SEK
Jan 1, 2022
-0.04 SEK
Jan 1, 2023
0.84 SEK
Jan 1, 2024
-0.65 SEK
Jan 1, 2025
3.73 SEK
The BioArctic Earnings Yield history
YEAREarnings YieldYoY
3.73 %-677.33%
-0.65 %-177.24%
0.84 %-2,150.89%
-0.04 %-90.67%
-0.44 %+74.83%
-0.25 %-177.45%
0.32 %-76.82%
1.39 %+2,417.66%
0.06 %-73.68%
0.21 %+1,452.02%
0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Earnings Yield of BioArctic is 3.73 % in 2025.

Earnings Yield of BioArctic changed from -0.65 % to 3.73 %, representing a -677.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield BioArctic since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioArctic

All Key Metrics — BioArctic